Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hammond

Showing results (581-590 of 711) with videos related to

Pageof 72
Sort By:
Environmental Research|April 27, 2020
A systematic review of empirical and simulation studies evaluating the health impact of transportation interventionsIvana Stankov, Leandro M T Garcia, Maria Antonietta Mascolli, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
British Journal of Cancer|July 22, 2004
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epitheliumR G Keedwell, Y Zhao, L A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancerRoy S Herbst, Lisa A Hammond, David P Carbone, et al.
Immunogenetics|July 25, 2018
Comparative MHC nomenclature: report from the ISAG/IUIS-VIC committee 2018Keith T Ballingall, Ronald E Bontrop, Shirley A Ellis, et al.
Nucleic Acids Research|December 1, 2016
IPD-MHC 2.0: an improved inter-species database for the study of the major histocompatibility complexGiuseppe Maccari, James Robinson, Keith Ballingall, et al.
Immunogenetics|November 30, 2019
Nomenclature report for killer-cell immunoglobulin-like receptors (KIR) in macaque species: new genes/alleles, renaming recombinant entities and IPD-NHKIR updatesJesse Bruijnesteijn, Natasja G de Groot, Nel Otting, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 28, 2018
Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney diseaseE A Swallow, M W Aref, N Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignanciesL A Hammond, J R Eckardt, S D Baker, et al.
Pageof 72

Showing results (581-590 of 711) with videos related to

Sort By:
Pageof 72
Environmental Research|April 27, 2020
A systematic review of empirical and simulation studies evaluating the health impact of transportation interventionsIvana Stankov, Leandro M T Garcia, Maria Antonietta Mascolli, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
British Journal of Cancer|July 22, 2004
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epitheliumR G Keedwell, Y Zhao, L A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancerRoy S Herbst, Lisa A Hammond, David P Carbone, et al.
Immunogenetics|July 25, 2018
Comparative MHC nomenclature: report from the ISAG/IUIS-VIC committee 2018Keith T Ballingall, Ronald E Bontrop, Shirley A Ellis, et al.
Nucleic Acids Research|December 1, 2016
IPD-MHC 2.0: an improved inter-species database for the study of the major histocompatibility complexGiuseppe Maccari, James Robinson, Keith Ballingall, et al.
Immunogenetics|November 30, 2019
Nomenclature report for killer-cell immunoglobulin-like receptors (KIR) in macaque species: new genes/alleles, renaming recombinant entities and IPD-NHKIR updatesJesse Bruijnesteijn, Natasja G de Groot, Nel Otting, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 28, 2018
Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney diseaseE A Swallow, M W Aref, N Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignanciesL A Hammond, J R Eckardt, S D Baker, et al.
Pageof 72